SV2A PET has been shown to be lower in patients with AD than in controls and is associated with variations in cognition, glucose hypometabolism, Aβ PET, and tau PET (7–17); however, only one of these research groups used [18F]SynVesT-1 (17). Here, MAPT is linked to Alzheimer disease.